Publications - 'D'
Publications 1351 - 1375 de 1753
| Titre | DOI |
|---|---|
|
Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in Real Life in Early Axial Spa? Results from the DESIR Cohort. A. Molto; B. Granger; D. Wendling; M.A. Breban; M. Dougados; L. Gossec 2014 |
|
|
Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in Real Life in Early Axial Spa? Results from the DESIR Cohort. A. Molto; B. Granger; D. Wendling; M.A. Breban; M. Dougados; L. Gossec 2014 |
|
|
Do typically and atypically developing children learn and generalize novel names similarly: The role of conceptual distance during learning and at test A. Witt; A. Comblain; J.P. Thibaut 2020 |
10.1016/j.ridd.2020.103720 |
|
Do upfront investments increase cooperation? A laboratory experiment F. Casoria; A. Ciccone 2021 |
10.1016/j.euroecorev.2021.103779 |
|
Do water managers perceive sustainable urban drainage systems as tools for an improved qualitative management of stormwater? A discourse analysis of the case of Lyon (France) E. Comby; A. Riviere-Honegger; M. Cottet; S. Ah-Leung; N. Cossais 2019 |
10.4000/developpementdurable.16082 |
|
Do we know enough to recommend corticosteroids in acute respiratory distress syndrome? M. Blot; A. Salmon-Rousseau; P. Chavanet; L. Piroth 2017 |
10.1186/s13054-017-1920-x |
|
Do we need congenital adrenal hyperplasia screening for premature infants? F. Huet; A. Godefroy; D. Cheillan; C. Somma; M. Roussey 2014 |
10.1016/j.arcped.2013.11.002 |
|
DO WE NEED MORE TIME TO GIVE LESS? EXPERIMENTAL EVIDENCE FROM TUNISIA G. Grolleau; A. Sutan; S.El Harbi; M. Jedidi 2018 |
10.1111/boer.12163 |
|
Do we need to replicate in sensory profiling studies? C. Peltier; N. Mammasse; M. Visalli; S. Cordelle; P. Schlich 2018 |
10.1016/j.foodqual.2017.09.001 |
|
Do we need to understand microbial communities to predict ecosystem function? A comparison of statistical models of nitrogen cycling processes E.B. Graham; W.R. Wieder; J.W. Leff; S.R. Weintraub; A.R. Townsend; C.C. Cleveland; L. Philippot; D.R. Nemergut 2014 |
10.1016/j.soilbio.2013.08.023 |
|
Do You Enjoy Having More Than Others or More Than Another? Exploring the Relationship Between Relative Concerns and the Size of the Reference Group J. Celse 2018 |
10.1007/s11205-017-1704-3 |
|
Do You Prefer Having More or More than Others in the Workplace? A Quasi-experimental Survey in Algeria L. Barbara; G. Grolleau; N. Mzoughi 2017 |
10.1002/mde.2806 |
|
Docetaxel, 5FU, oxaliplatin (TEFOX) in 1st line treatment of signet ring cell and/or poorly differentiated gastric adenocarcinoma: a retrospective study of AGEO S. Pernot; O. Dubreuil; D. Tougeron; D. Soudan; J.Baptiste Bachet; C. Lepere; K. Le Malicot; J. Taieb; P. Rougier 2015 |
10.1200/jco.2015.33.15_suppl.e15048 |
|
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study) S. Kim; M. Jary; T. Andre; V. Vendrely; B. Buecher; E. Francois; F.C. Bidard; S. Dumont; E. Samalin; D. Peiffert; S. Pernot; N. Baba-Hamed; F.El Hajbi; O. Bouche; J. Desrame; A. Parzy; M. Zoubir; C. Louvet; J.B. Bachet; T. Nguyen; M. Ben Abdelghani; D. Smith; C. de la Fouchardiere; T. Aparicio; J. Bennouna; J.M. Gornet; M. Jacquin; F. Bonnetain; C. Borg 2017 |
10.1186/s12885-017-3566-0 |
|
Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study) S. Kim; E. Francois; F.C. Bidard; E. Samalin; E. Hajbi; N. Baba-Hamed; S. Dumont; S. Pernot; D. Peiffert; F. Ghiringhelli; O. Bouche; J. Desrame; M. Zoubir; A. Parzy; D. Smith; C. de la Fouchardiere; B. Buecher; V. Vendrely; F. Bonnetain; C. Borg 2017 |
|
|
Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study) S. Kim; E. Francois; F.C. Bidard; E. Samalin; E. Hajbi; N. Baba-Hamed; S. Dumont; S. Pernot; D. Peiffert; F. Ghiringhelli; O. Bouche; J. Desrame; M. Zoubir; A. Parzy; D. Smith; C. de la Fouchardiere; B. Buecher; V. Vendrely; F. Bonnetain; C. Borg 2017 |
|
|
Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma F. Fiteni; S. Paget-Bailly; M. Messager; T. N'Guyen; Z. Lakkis; P. Mathieu; N. Lamfichekh; A. Picard; B. Benzidane; D. Cleau; F. Bonnetain; C. Borg; C. Mariette; S. Kim 2016 |
10.1002/cam4.885 |
|
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study S. Kim; E. Francois; T. Andre; E. Samalin; M. Jary; F.El Hajbi; N. Baba-Hamed; S. Pernot; M.C. Kaminsky; O. Bouche; J. Desrame; M. Zoubir; F. Ghiringhelli; A. Parzy; C. de la Fouchardiere; D. Smith; M. Deberne; L. Spehner; N. Badet; O. Adotevi; A. Anota; A. Meurisse; D. Vernerey; J. Taieb; V. Vendrely; B. Buecher; C. Borg 2018 |
10.1016/S1470-2045(18)30321-8 |
|
Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model C. Mirjolet; J. Boudon; A. Loiseau; S. Chevrier; R. Boidot; A. Oudot; B. Collin; E. Martin; P.Alias Joy; N. Millot; G. Crehange 2017 |
10.2147/IJN.S139167 |
|
DOCK8 Mutation Syndrome: A Diagnostic Challenge for Dermatologists J. Moreau; S. Beaussant-Cohen; F. Aubin; P.S. Rohrlich; E. Puzenat 2016 |
10.2340/00015555-2288 |
|
Docosahexaenoic Acid Attenuates Mitochondrial Alterations and Oxidative Stress Leading to Cell Death Induced by Very Long-Chain Fatty Acids in a Mouse Oligodendrocyte Model T. Nury; M. Doria; G. Lizard; A. Vejux 2020 |
10.3390/ijms21020641 |
|
DOCOSAHEXAENOIC ACID INDUCES COLON CANCER CELL DEATH THROUGH AMPKalpha/FOXO3A/MIR-21 PATHWAY A. Dumont; A. Hichami; V. Derangere; C. Rebe; C. Thomas; F. Ghiringhelli; M. Rialland; A. Fluckiger 2015 |
|
|
DOCOSAHEXAENOIC ACID INDUCES COLON CANCER CELL DEATH THROUGH AMPKalpha/FOXO3A/MIR-21 PATHWAY A. Dumont; A. Hichami; V. Derangere; C. Rebe; C. Thomas; F. Ghiringhelli; M. Rialland; A. Fluckiger 2015 |
|
|
Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1 beta secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment A. Dumont; C. de Rosny; T.L.V. Kieu; S. Perrey; H. Berger; A. Fluckiger; T. Muller; J.P.Pais de Barros; L. Pichon; A. Hichami; C. Thomas; C. Rebe; F. Ghiringhelli; M. Rialland 2019 |
10.1038/s41419-019-1723-x |
|
Docosahexaenoic acid modulates oxidative stress-induced apoptosis via PI3K/Akt m-TOR/p70S6K pathways in human RPE cells B. Narjes; D.A. Aline; L. Laurent; B. Benedicte; M. Lucy; G. Stephane; B. Lionel 2015 |
10.1002/ejlt.201400155 |